We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+82%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$209M
AUM Growth
+$44M
Cap. Flow
-$21.4M
Cap. Flow %
-10.24%
Top 10 Hldgs %
42.68%
Holding
94
New
26
Increased
5
Reduced
16
Closed
34

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$5.81M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.8M
3
ELVN icon
Enliven Therapeutics
ELVN
+$4.43M
4
WVE icon
Wave Life Sciences
WVE
+$4.28M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$4.06M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$8.17M
2
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$4.16M
3
ETNB
89bio
ETNB
+$4.02M
4
COGT icon
Cogent Biosciences
COGT
+$3.88M
5
APGE icon
Apogee Therapeutics
APGE
+$3.75M

Sector Composition

Rank Sector Weight
1 Healthcare 96.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
51
Corbus Pharmaceuticals
CRBP
$166M
$1.14M 0.54%
139,543
-90,419
-39% -$1.12M
FULC icon
52
Fulcrum Therapeutics
FULC
$273M
$1.04M 0.5%
92,055
-6,744
-7% -$68.6K
ESTA icon
53
Establishment Labs
ESTA
$2.72B
$955K 0.46%
13,100
– –
RARE icon
54
CALL
Ultragenyx Pharmaceutical
RARE
$2.45B
$810K 0.39%
+35,200
New +$1.16M
ALMS
55
PUT
Alumis Inc
ALMS
$3.6B
$519K 0.25%
+53,200
New +$371K
ALDX icon
56
CALL
Aldeyra Therapeutics
ALDX
$92.9M
$518K 0.25%
+100,000
New +$514K
RAPT
57
DELISTED
RAPT Therapeutics
RAPT
$481K 0.23%
+14,194
New +$441K
PGEN icon
58
PUT
Precigen
PGEN
$2.24B
$418K 0.2%
100,000
– –
ABUS icon
59
Arbutus Biopharma
ABUS
$857M
$363K 0.17%
75,484
– –
SLNO
60
PUT
DELISTED
Soleno Therapeutics
SLNO
$328K 0.16%
+7,100
New +$389K
ACAD icon
61
PUT
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-20,000
Closed -$427K
AKRO
62
DELISTED
Akero Therapeutics
AKRO
– –
-58,579
Closed -$2.78M
APGE icon
63
Apogee Therapeutics
APGE
$10.1B
– –
-94,400
Closed -$3.75M
ARCT icon
64
PUT
Arcturus Therapeutics
ARCT
$164M
– –
-50,000
Closed -$922K
AVTX icon
65
Avalo Therapeutics
AVTX
$965M
– –
-100,036
Closed -$1.27M
CNTA
66
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-88,024
Closed -$2.13M
CNTA
67
PUT
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-25,000
Closed -$606K
COGT icon
68
CALL
Cogent Biosciences
COGT
$6.65B
– –
-45,000
Closed -$646K
COR icon
69
Cencora
COR
$60.6B
– –
-6,000
Closed -$1.88M
CVS icon
70
CVS Health
CVS
$133B
– –
-43,600
Closed -$3.29M
ETNB
71
DELISTED
89bio
ETNB
– –
-273,661
Closed -$4.02M
GERN icon
72
Geron
GERN
$828M
– –
-1,858,354
Closed -$2.55M
IMUX icon
73
Immunic
IMUX
$190M
– –
-17,390
Closed -$153K
INSP icon
74
Inspire Medical Systems
INSP
$1.45B
– –
-18,600
Closed -$1.38M
KPTI icon
75
PUT
Karyopharm Therapeutics
KPTI
$43.5M
– –
-48,100
Closed -$315K
1 2
3
4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
CA
Carson Advisory Athens, Georgia $193M AUM 14.52% 1-Year Est. Return

Exome Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Exome Asset Management held 94 positions worth $209M, up 27% from $165M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Exome Asset Management withdrew a net $21.4M in Q4 2025, closing 34 positions and reducing 16 holdings. Its most notable exit was 89bio, an estimated $4.02M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier.

Against the trend, Exome Asset Management opened a new position in Elevance Health worth $6.03M.

  • Exome Asset Management's largest Q4 2025 buy was Elevance Health: 17,191 shares worth $6.03M.
  • Exome Asset Management added most to Universal Health Services in Q4 2025, an estimated $2.14M increase.
  • Exome Asset Management's biggest Q4 2025 reduction was Praxis Precision Medicines, cutting an estimated $8.17M.
  • Exome Asset Management fully exited 89bio in Q4 2025, selling an estimated $4.02M.
  • Exome Asset Management's ten largest holdings make up 43% of its $209M portfolio in Q4 2025.
  • Exome Asset Management opened 26 new positions and closed 34 in Q4 2025.
  • Exome Asset Management's portfolio value rose 27% quarter-over-quarter to $209M.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.